GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » Shiller PE Ratio

ProPhase Labs (ProPhase Labs) Shiller PE Ratio : 25.42 (As of May. 01, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ProPhase Labs Shiller PE Ratio?

As of today (2024-05-01), ProPhase Labs's current share price is $4.575. ProPhase Labs's E10 for the quarter that ended in Dec. 2023 was $0.18. ProPhase Labs's Shiller PE Ratio for today is 25.42.

The historical rank and industry rank for ProPhase Labs's Shiller PE Ratio or its related term are showing as below:

PRPH' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.56   Med: 44.55   Max: 200
Current: 25.61

During the past years, ProPhase Labs's highest Shiller PE Ratio was 200.00. The lowest was 15.56. And the median was 44.55.

PRPH's Shiller PE Ratio is ranked better than
55.13% of 78 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.045 vs PRPH: 25.61

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

ProPhase Labs's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.510. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.18 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


ProPhase Labs Shiller PE Ratio Historical Data

The historical data trend for ProPhase Labs's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs Shiller PE Ratio Chart

ProPhase Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.86 116.71 48.50 35.92 25.80

ProPhase Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.92 27.91 26.85 18.82 25.80

Competitive Comparison of ProPhase Labs's Shiller PE Ratio

For the Diagnostics & Research subindustry, ProPhase Labs's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProPhase Labs's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Shiller PE Ratio falls into.



ProPhase Labs Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ProPhase Labs's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=4.575/0.18
=25.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProPhase Labs's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, ProPhase Labs's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.51/129.4194*129.4194
=-0.510

Current CPI (Dec. 2023) = 129.4194.

ProPhase Labs Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.050 99.695 -0.065
201406 -0.190 100.560 -0.245
201409 -0.180 100.428 -0.232
201412 -0.030 99.070 -0.039
201503 -0.090 99.621 -0.117
201506 -0.100 100.684 -0.129
201509 0.040 100.392 0.052
201512 -0.070 99.792 -0.091
201603 -0.080 100.470 -0.103
201606 -0.070 101.688 -0.089
201609 0.010 101.861 0.013
201612 -0.040 101.863 -0.051
201703 2.470 102.862 3.108
201706 -0.140 103.349 -0.175
201709 -0.050 104.136 -0.062
201712 0.160 104.011 0.199
201803 0.004 105.290 0.005
201806 -0.020 106.317 -0.024
201809 -0.090 106.507 -0.109
201812 -0.040 105.998 -0.049
201903 -0.090 107.251 -0.109
201906 -0.110 108.070 -0.132
201909 -0.040 108.329 -0.048
201912 -0.040 108.420 -0.048
202003 -0.070 108.902 -0.083
202006 0.010 108.767 0.012
202009 -0.040 109.815 -0.047
202012 -0.080 109.897 -0.094
202103 0.060 111.754 0.069
202106 -0.090 114.631 -0.102
202109 -0.260 115.734 -0.291
202112 0.700 117.630 0.770
202203 0.680 121.301 0.726
202206 0.400 125.017 0.414
202209 0.060 125.227 0.062
202212 -0.160 125.222 -0.165
202303 0.030 127.348 0.030
202306 -0.200 128.729 -0.201
202309 -0.300 129.860 -0.299
202312 -0.510 129.419 -0.510

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ProPhase Labs  (NAS:PRPH) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


ProPhase Labs Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ProPhase Labs (ProPhase Labs) Business Description

Traded in Other Exchanges
N/A
Address
711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Executives
Morse Robert A. Jr. officer: Controller 711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White officer: Chief Financial Officer 191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr director 902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel 10 percent owner C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus 10 percent owner 188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch director 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady officer: Chief Accounting Officer 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr officer: Chief Operating Officer PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal 10 percent owner THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank director 104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin director
Mark A. Burnett 10 percent owner 40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley director, 10 percent owner, officer: Chairman, President, CEO C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo 10 percent owner 17 WOLCOTT COURT, BOSTON MA 02136

ProPhase Labs (ProPhase Labs) Headlines

From GuruFocus

ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute

By Value_Insider Value_Insider 11-08-2022